AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18572080 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir 400 mg twice daily (n=1637)
Number of subjects: 3172
Study 18572080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=1640)
Number of subjects: 3172
Study 18572080 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir 400 mg twice daily
Number of subjects: 3172
Study 16094268 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CRM
Number of subjects: 74
Study 16094268 — intervention group
Group type: COMPARATOR
Intervention: ICBG
Number of subjects: 74
Study 12452026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of warm (43 degrees C‐45 degrees C) distilled water (1,250 ml/m2) plus 5‐fluorouracil (500 mg/L) after radical gastrectomy
Number of subjects: 50
Study 12452026 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal infusion of warm (43 degrees C‐45 degrees C) distilled water (1,250 ml/m2) plus 5‐fluorouracil (500 mg/L) before operation
Number of subjects: 50
Study 11116771 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 323
Study 11116771 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 323
Study 11116771 — intervention group
Group type: COMPARATOR
Intervention: Patient preference for treatment
Number of subjects: 323
Study 9105813 — intervention group
Group type: EXPERIMENTAL
Intervention: St. Jude (SJ) valve
Number of subjects: 80
Study 9105813 — intervention group
Group type: COMPARATOR
Intervention: Medtronic Hall (MH) valve
Number of subjects: 80
Study 1486900 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics (e.g. furosemide 40 mg, torasemide 5 and 10 mg)
Number of subjects: 30
Study 1486900 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 30
Study 1486900 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics (muzolimine 20 mg, torasemide 2.5 mg)
Number of subjects: 30
Study 1486900 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretics (e.g. hydrochlorothiazide 25 and 50 mg, xipamide 10, 20 and 40 mg)
Number of subjects: 30
Study 1486900 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics
Number of subjects: 30
Study 2428187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregation inhibitors, low heparin dosage, and preoperative normovolaemic haemodilution
Number of subjects: 0
Study 2428187 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30928824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran dual therapy (110 or 150 mg bid, plus clopidogrel or ticagrelor)
Number of subjects: 0
Study 30928824 — intervention group
Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 0
Study 30928824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran dual therapy (110 or 150 mg)
Number of subjects: 0
Study 29779020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (4 g/day for 72 postoperative hours)
Number of subjects: 140
Study 29779020 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 140
Study 26915299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation in upright position (IPVR) for 20 minutes, 2 hours after feeding
Number of subjects: 50
Study 25686117 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive treatment
Number of subjects: 95
Study 25686117 — intervention group
Group type: COMPARATOR
Intervention: Reactive treatment
Number of subjects: 95
Study 23921857 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ibuprofen (800 mg starting 1 hour before misoprostol, then every 4-6 hours for 48 hours regardless of pain)
Number of subjects: 250
Study 23921857 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ibuprofen (800 mg every 4-6 hours as needed for pain)
Number of subjects: 250
Study 23921857 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ibuprofen
Number of subjects: 250
Study 23921857 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ibuprofen
Number of subjects: 250
Study 23921857 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study 19879035 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus oral azathioprine for 24 months (AZA group)
Number of subjects: 46
Study 19879035 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus intravenous cyclophosphamide pulses (CIC group)
Number of subjects: 46
Study 19879035 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 18379360 — intervention group
Group type: EXPERIMENTAL
Intervention: I 160 mg/m(2) plus D 60 mg/m(2) on day 1 every 21 days (arm A)
Number of subjects: 65
Study 18379360 — intervention group
Group type: EXPERIMENTAL
Intervention: I 80 mg/m(2) on days 1,8 plus D 60 mg/m(2) on day 1 every 21 days (arm B)
Number of subjects: 65
Study 18379360 — intervention group
Group type: EXPERIMENTAL
Intervention: I 60 mg/m(2) plus D 30 mg/m(2) on days 1, 8, 15, and 22 every 42 days (arm C)
Number of subjects: 65
Study 16601869 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) administration (25 mg/kg per day, divided into three daily doses)
Number of subjects: 4
Study 14617464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular iron dextran
Number of subjects: 60
Study 14617464 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulphate
Number of subjects: 60
Study 10887918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 829
Study 10887918 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 829
Study 8814046 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' perceptions of asthma severity
Number of subjects: 323
Study 8814046 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication severity rating
Number of subjects: 323
Study 8814046 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal variation rating
Number of subjects: 323
Study 8814046 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening peak expiratory flow rate percentage
Number of subjects: 323
Study 1403033 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating doses of doxorubicin and cyclophosphamide with vincristine and prednisone followed by 1 year of leukocyte alpha-interferon
Number of subjects: 319
Study 1403033 — intervention group
Group type: COMPARATOR
Intervention: Escalating doses of doxorubicin and cyclophosphamide with vincristine and prednisone
Number of subjects: 319
Study 1403033 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin administered by continuous infusion
Number of subjects: 319
Study 31133585 — intervention group
Group type: EXPERIMENTAL
Intervention: BHiRCH intervention (early warning tool, care pathway, structured communication method)
Number of subjects: 14
Study 31133585 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 14
Study 28801165 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Intervention with a child care health consultant (CCHC) in Year 1
Number of subjects: 32
Study 28801165 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (contrast) group
Number of subjects: 32
Study 25660356 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 353
Study 25660356 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 353
Study 25660356 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg
Number of subjects: 353
Study 23422453 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration therapy (twice a week for 3 months)
Number of subjects: 89
Study 23422453 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy treatment (PT)
Number of subjects: 89
Study 20525942 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2 mg/kg/day)
Number of subjects: 41
Study 20525942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 20525942 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5 mg/kg/day)
Number of subjects: 41
Study 20573584 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 70
Study 20573584 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70
Study 17257238 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 50
Study 17257238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15097434 — intervention group
Group type: EXPERIMENTAL
Intervention: HL-450 (AR milk thickened with 0.45 g/100 mL LBG)
Number of subjects: 30
Study 15097434 — intervention group
Group type: EXPERIMENTAL
Intervention: HL-350 (AR milk with reduced concentration of 0.35 g/100 mL LBG)
Number of subjects: 30
Study 15097434 — intervention group
Group type: COMPARATOR
Intervention: Control milk (HL-00; no LBG)
Number of subjects: 30
Study 15097434 — intervention group
Group type: EXPERIMENTAL
Intervention: HL-450
Number of subjects: 30
Study 15097434 — intervention group
Group type: EXPERIMENTAL
Intervention: HL-350
Number of subjects: 30
Study 12208906 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual traction
Number of subjects: 87
Study 12208906 — intervention group
Group type: COMPARATOR
Intervention: Fracture-table traction
Number of subjects: 87
Study 9639214 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps delivery
Number of subjects: 44
Study 9639214 — intervention group
Group type: COMPARATOR
Intervention: Vacuum delivery
Number of subjects: 44
Study 8613331 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml BCG vaccine at birth
Number of subjects: 238
Study 8613331 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 ml BCG vaccine at birth
Number of subjects: 238
Study 8613331 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml BCG vaccine at 4-6 weeks
Number of subjects: 238
Study 8613331 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.1 ml BCG at birth)
Number of subjects: 238
Study 2813804 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 9
Study 2813804 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study 1091940 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg during detoxification
Number of subjects: 0
Study 1091940 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg during detoxification
Number of subjects: 0
Study 1091940 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg given 2 hrs before 30 mg morphine i.v.
Number of subjects: 0
Study 1091940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control) during detoxification
Number of subjects: 0
Study 1091940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control) given 2 hrs before morphine
Number of subjects: 0
Study 31626050 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (3, 4, 5 months)
Number of subjects: 0
Study 31626050 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (2, 4, 6 months)
Number of subjects: 0
Study 31626050 — intervention group
Group type: COMPARATOR
Intervention: PCV13 (3, 5 months)
Number of subjects: 0
Study 28716230 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β-1a injected subcutaneously three times weekly (IFN β‐1a SC tiw)
Number of subjects: 0
Study 28716230 — intervention group
Group type: COMPARATOR
Intervention: Interferon β-1a injected intramuscularly once weekly (IFN β‐1a IM qw)
Number of subjects: 0
Study 28716230 — intervention group
Group type: COMPARATOR
Intervention: Interferon β-1a IM qw
Number of subjects: 0
Study 28716230 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β-1a SC tiw
Number of subjects: 0
Study 27845597 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical information about benefits and harms of cervical screening
Number of subjects: 1000
Study 27845597 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical information specific to HPV-vaccinated women
Number of subjects: 1000
Study 27845597 — intervention group
Group type: COMPARATOR
Intervention: No information
Number of subjects: 1000
Study 27845597 — intervention group
Group type: COMPARATOR
Intervention: Non-numerical information
Number of subjects: 1000
Study 25288125 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.018-inch bracket slot system
Number of subjects: 216
Study 25288125 — intervention group
Group type: COMPARATOR
Intervention: 0.022-inch bracket slot system
Number of subjects: 216
Study 23021098 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview (BNI)
Number of subjects: 342
Study 19940322 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 45
Study 19940322 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 45
Study 19940322 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 45
Study 17710008 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (5 g)
Number of subjects: 60
Study 17710008 — intervention group
Group type: COMPARATOR
Intervention: Control group (neomycin ointment 5 g)
Number of subjects: 60
Study 15596745 — intervention group
Group type: EXPERIMENTAL
Intervention: IV immunoglobulins (IVIg) 1 g/kg
Number of subjects: 76
Study 15596745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1% human albumin)
Number of subjects: 76
Study 11516593 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent treatment (smoking cessation intervention initiated two weeks after admission)
Number of subjects: 36
Study 11516593 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (smoking cessation intervention initiated six weeks after admission)
Number of subjects: 36
Study 9577422 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 372
Study 7833096 — intervention group
Group type: COMPARATOR
Intervention: MACC chemotherapy
Number of subjects: 151
Study 7833096 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC chemotherapy + Lonidamine (LND) 150 mg orally three times daily
Number of subjects: 151
Study 7833096 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC chemotherapy + LND
Number of subjects: 151
Study 7833096 — intervention group
Group type: COMPARATOR
Intervention: MACC chemotherapy (control)
Number of subjects: 151
Study 3240760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine jelly and spray combination
Number of subjects: 94
Study 3240760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine jelly alone
Number of subjects: 94
Study 3240760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine spray alone
Number of subjects: 94
Study 3240760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lignocaine)
Number of subjects: 94
Study 31958099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spine orthosis (n=23)
Number of subjects: 50
Study 31958099 — intervention group
Group type: COMPARATOR
Intervention: No lumbar spine orthosis (n=27)
Number of subjects: 50
Study 31230007 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone plus daily placebo dose-extension (PDE)
Number of subjects: 120
Study 31230007 — intervention group
Group type: COMPARATOR
Intervention: Methadone/treatment as usual (control)
Number of subjects: 120
Study 31230007 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 120
Study 28474311 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUS-guided compression on bleeding biopsy tracts immediately after prostate biopsy
Number of subjects: 148
Study 28474311 — intervention group
Group type: COMPARATOR
Intervention: TRUS-guided prostate biopsy alone (non-compression group)
Number of subjects: 148
Study 28474311 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUS-guided compression
Number of subjects: 148
Study 25875868 — intervention group
Group type: EXPERIMENTAL
Intervention: Study vaccine (trivalent, inactivated split influenza vaccine)
Number of subjects: 405
Study 25875868 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (commercially available trivalent, inactivated split influenza vaccine)
Number of subjects: 405
Study 23928664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 17
Study 23928664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 21545398 — intervention group
Group type: EXPERIMENTAL
Intervention: aliskiren/HCTZ 150/12.5 mg, titrated to 300/25 mg
Number of subjects: 332
Study 21545398 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 5 mg, titrated to 10 mg
Number of subjects: 332
Study 21545398 — intervention group
Group type: EXPERIMENTAL
Intervention: aliskiren/HCTZ
Number of subjects: 332
Study 21545398 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 332
Study 19549078 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 29
Study 19549078 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 29
Study 17971584 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 methylated tumors
Number of subjects: 177
Study 17971584 — intervention group
Group type: COMPARATOR
Intervention: COX‐2 expression (IHC)
Number of subjects: 177
Study 16215314 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral injection of 100 units of botulinum A toxin (n=20)
Number of subjects: 30
Study 16215314 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment as controls (n=10)
Number of subjects: 30
Study 11850304 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0
Study 9988956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive antihypertensive treatment to achieve a goal diastolic blood pressure of 80 mm Hg or lower
Number of subjects: 0
Study 9988956 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day
Number of subjects: 0
Study 9988956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7767417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup (5 mg/kg per dose)
Number of subjects: 70
Study 7767417 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen syrup (10 mg/kg per dose)
Number of subjects: 70
Study 2252040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg twice a day)
Number of subjects: 87
Study 2252040 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (400 mg four times a day)
Number of subjects: 87
Study 7018669 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 60
Study 7018669 — intervention group
Group type: COMPARATOR
Intervention: Non-BCG treatment
Number of subjects: 60
Study 31707634 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA) stimulation at the lower leg
Number of subjects: 60
Study 31707634 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA) stimulation at the ear
Number of subjects: 60
Study 31707634 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA) stimulation at the abdomen
Number of subjects: 60
Study 31707634 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA) stimulation at the forearm
Number of subjects: 60
Study 31707634 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 27149653 — intervention group
Group type: EXPERIMENTAL
Intervention: Hb content-based study group
Number of subjects: 89
Study 27149653 — intervention group
Group type: COMPARATOR
Intervention: Unit-based control group
Number of subjects: 89
Study 25857500 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya yoga (SKY) intervention
Number of subjects: 61
Study 25857500 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (O-SOC)
Number of subjects: 61
Study 23823808 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ERCP somatostatin (0.5 mg/h for 24 hours, starting 1 hour prior to ERCP)
Number of subjects: 124
Study 23823808 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ERCP somatostatin (0.5 mg/h for 24 hours, starting 1 hour after ERCP)
Number of subjects: 124
Study 23823808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline for 24 hours, starting 1 hour prior to ERCP)
Number of subjects: 124
Study 21805410 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic mixture
Number of subjects: 66
Study 21805410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 19791493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic system (P‐max Newtron)
Number of subjects: 399
Study 19791493 — intervention group
Group type: COMPARATOR
Intervention: Conventional round bur
Number of subjects: 399
Study 16309498 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vitiligo
Number of subjects: 57
Study 14971716 — intervention group
Group type: EXPERIMENTAL
Intervention: Mao-to (herbal medicine)
Number of subjects: 18
Study 11711931 — intervention group
Group type: EXPERIMENTAL
Intervention: SpaceMaker balloon-assisted advancement flap technique
Number of subjects: 40
Study 11711931 — intervention group
Group type: COMPARATOR
Intervention: Advancement flap, turnover flap, transposition flap
Number of subjects: 40
Study 9024039 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 41
Study 9024039 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 41
Study 9024039 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 41
Study 9024039 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation
Number of subjects: 41
Study 8428715 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cefuroxime (group 1)
Number of subjects: 104
Study 8428715 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective parenteral and enteral antimicrobial regimen (group 2)
Number of subjects: 104
Study 8428715 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective parenteral and enteral antimicrobial regimen (group 3)
Number of subjects: 104
Study 8428715 — intervention group
Group type: COMPARATOR
Intervention: No initial antimicrobials until clinically indicated (group 4)
Number of subjects: 104
Study 8428715 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective parenteral and enteral antimicrobial regimen (groups 2 and 3)
Number of subjects: 104